Johnson & Johnson's (JNJ) Janssen Biotech unit received the US Food and Drug Administration's approval for the Tec-Dara drug combination to treat adults with multiple myeloma who have received at least one prior therapy, the health regulator said Thursday.

A late-stage clinical trial showed the combination reduced the risk of the condition worsening or fatality by 83% compared with the usual treatments, the FDA said.

The FDA added that this supporting clinical data also transitioned the standalone Tecvayli medication from an accelerated clearance to a conventional approval.

Price: 237.28, Change: -8.03, Percent Change: -3.27